JP7592320B2 - ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物 - Google Patents
ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物 Download PDFInfo
- Publication number
- JP7592320B2 JP7592320B2 JP2021534405A JP2021534405A JP7592320B2 JP 7592320 B2 JP7592320 B2 JP 7592320B2 JP 2021534405 A JP2021534405 A JP 2021534405A JP 2021534405 A JP2021534405 A JP 2021534405A JP 7592320 B2 JP7592320 B2 JP 7592320B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- seq
- sortilin
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/083—Neurotensin
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722726P | 2018-08-24 | 2018-08-24 | |
| US62/722,726 | 2018-08-24 | ||
| US201962804063P | 2019-02-11 | 2019-02-11 | |
| US62/804,063 | 2019-02-11 | ||
| PCT/CA2019/051170 WO2020037434A1 (en) | 2018-08-24 | 2019-08-26 | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021535209A JP2021535209A (ja) | 2021-12-16 |
| JP2021535209A5 JP2021535209A5 (https=) | 2022-08-29 |
| JPWO2020037434A5 JPWO2020037434A5 (https=) | 2022-08-29 |
| JP7592320B2 true JP7592320B2 (ja) | 2024-12-02 |
Family
ID=69591094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534405A Active JP7592320B2 (ja) | 2018-08-24 | 2019-08-26 | ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220000971A1 (https=) |
| EP (1) | EP3844190A4 (https=) |
| JP (1) | JP7592320B2 (https=) |
| CN (1) | CN113286820B (https=) |
| AU (1) | AU2019324747A1 (https=) |
| CA (1) | CA3110414A1 (https=) |
| IL (1) | IL281043A (https=) |
| WO (1) | WO2020037434A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107708733B (zh) | 2015-04-07 | 2022-11-15 | 艾利妥 | 抗分拣蛋白抗体和其使用方法 |
| CA3006313C (en) | 2015-11-24 | 2020-02-11 | Transfert Plus, S.E.C. | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy |
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| TWI809147B (zh) | 2018-07-13 | 2023-07-21 | 美商阿列克特有限責任公司 | 抗分揀蛋白抗體及其使用方法 |
| CN116731113A (zh) * | 2022-03-01 | 2023-09-12 | 上海智肽生物科技有限公司 | 针对sort1的多肽化合物及其药物偶联物 |
| CN119403786A (zh) | 2022-06-23 | 2025-02-07 | 德罗普尼尔生物有限公司 | 选择性诱导细胞外靶标在溶酶体中降解的双功能分子 |
| CN120641133A (zh) * | 2022-11-14 | 2025-09-12 | 瑟瑞技术公司 | 用于刺激抗肿瘤免疫应答的药物缀合物化合物 |
| WO2025054707A1 (en) * | 2023-09-11 | 2025-03-20 | Theratechnologies Inc. | Peptide conjugates of camptothecin analogs and uses thereof |
| WO2025208212A1 (en) * | 2024-04-02 | 2025-10-09 | Theratechnologies Inc. | Combination therapies comprising peptide-drug conjugates targeting sortilin |
| WO2025236098A1 (en) * | 2024-05-16 | 2025-11-20 | Theratechnologies Inc. | Peptide conjugates of maytansinoids and uses thereof |
| WO2026021513A1 (zh) * | 2024-07-25 | 2026-01-29 | 上海湃鸿生物科技有限公司 | 一种多肽药物偶联物及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017088058A1 (en) | 2015-11-24 | 2017-06-01 | Transfert Plus, S.E.C. | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016270874B2 (en) * | 2015-06-03 | 2018-12-06 | Tairx, Inc. | Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry |
-
2019
- 2019-08-26 US US17/270,787 patent/US20220000971A1/en active Pending
- 2019-08-26 CA CA3110414A patent/CA3110414A1/en active Pending
- 2019-08-26 AU AU2019324747A patent/AU2019324747A1/en active Pending
- 2019-08-26 EP EP19852741.8A patent/EP3844190A4/en active Pending
- 2019-08-26 WO PCT/CA2019/051170 patent/WO2020037434A1/en not_active Ceased
- 2019-08-26 JP JP2021534405A patent/JP7592320B2/ja active Active
- 2019-08-26 CN CN201980069301.0A patent/CN113286820B/zh active Active
-
2021
- 2021-02-23 IL IL281043A patent/IL281043A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017088058A1 (en) | 2015-11-24 | 2017-06-01 | Transfert Plus, S.E.C. | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021535209A (ja) | 2021-12-16 |
| CN113286820B (zh) | 2025-04-08 |
| AU2019324747A1 (en) | 2021-04-01 |
| WO2020037434A1 (en) | 2020-02-27 |
| CN113286820A (zh) | 2021-08-20 |
| EP3844190A4 (en) | 2022-06-08 |
| CA3110414A1 (en) | 2020-02-27 |
| IL281043A (en) | 2021-04-29 |
| EP3844190A1 (en) | 2021-07-07 |
| US20220000971A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7592320B2 (ja) | ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物 | |
| JP7158547B2 (ja) | Ｍｕｃ１に特異的に結合する抗体及びその用途 | |
| TWI772288B (zh) | 基於艾日布林之抗體-藥物結合物及使用方法 | |
| JP2026048884A (ja) | がんを有する対象においてがんを処置することに用いるための抗ｍｅｆｌｉｎ抗体、および当該抗体を含む医薬組成物 | |
| Liu et al. | High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates | |
| JP7659326B2 (ja) | ヒト化抗ｇｐｃ－１抗体 | |
| US20250312468A1 (en) | Anti-protac antibodies and complexes | |
| WO2021251460A1 (ja) | Ｃａｆを有するがんを処置するための組成物 | |
| EP4491632A1 (en) | Ror1-targeted binding molecule and use thereof | |
| EP4642482A1 (en) | Vhh anti-protac antibodies and complexes | |
| Zhou et al. | h3B7A-LDM, a novel anti-mesothelin antibody-drug conjugate with the potential to induce antitumor immunity, shows potent efficacy against solid tumors | |
| HK40117209A (zh) | 一种靶向ror1的结合分子及其应用 | |
| HK40117209B (zh) | 一种靶向ror1的结合分子及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20210421 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220819 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220819 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230815 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231030 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240619 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240708 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241022 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241113 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7592320 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |